Benzinga | Jul 15, 2020 09:21AM EDT

Stifel Downgrades GW Pharmaceuticals to Hold, Lowers Price Target to $140

Stifel analyst Paul Matteis downgrades GW Pharmaceuticals (NASDAQ:GWPH) from Buy to Hold and lowers the price target from $150 to $140.